The increasing commercialization of cell therapies comes with a growing need to streamline manufacturing workflows in compliance with regulatory standards. Scientists engaged in research and development of clinical cell therapeutics, such as CAR T cell therapy, must mitigate the risks associated with inconsistent, underperforming, or unreliable reagents and equipment. Scalable clinical manufacturing workflows depend on the efficiency and functionality of technologies that researchers adopt in the early stages of cell therapy manufacturing.
Download this application note from Thermo Fisher Scientific to learn how technologies such as large-volume electroporation equipment can streamline cell therapy manufacturing workflows and improve the reliability of long-term commercialization efforts.
